地特胰岛素的体重优势:从基础到临床
被引量：2
Insulin determir improves glycaemic control with lower weight gain:basic science to the clinic
摘要
体重增加是胰岛素治疗的主要障碍之一。地特胰岛素不仅能有效改善血糖控制,降低低血糖风险,还具有减少体重增加的优势。其机制可能通过抑制中枢减少能量摄人、恢复生理性肝脏/外周胰岛素梯度、减少防御性进食及减少脂肪含量等作用实现的。
出处
《药品评价》
CAS
2013年第11期44-47,共4页
Drug Evaluation
参考文献9
-
1P. Hollander,J. Cooper,J. Bregnhoj.A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes[].Clinical Therapeutics.2008 被引量：1
-
2Eurovean Diabetes Policy Group.A desktop guide to type 2 diabetes mellitus[].Diabetic Medicine.1999 被引量：1
-
3Holman RR,Farmer AJ,Davies MJ,et al.Three-year efficacy of complex insulin regimens in type 2 diabetes[].IN Engl J Med.2009 被引量：1
-
4Bott S,Tusek C,Jacobsen LV,et al.Insulin detemir under steady-state conditions:no accumulation and constant metabolic effect over time with twice daily administration in subjects with Type 1 diabetes[].Diabets Med.2006 被引量：1
-
5Valensi P,Benroubi M,Borzi V,et al.Initiating insulin therapy with,or switching existing insulin therapy to biphasic insulin aspart 30/70 (NovoMix 30 ) in routine care;safety and effectiveness in patients with type 2 diabetes in the IMPROVE observational study[].International Journal of Clinical Practice.2009 被引量：1
-
6UK Prospective Diabetes Study Group.Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes[].The Lancet.1998 被引量：1
-
7RUSSELL-JONES D.Insulin detemir:Improving the predictabilityof glycaemic control[].International Journal of Obesity and Related Metabolic Disorders.2004 被引量：1
-
8UK Prospective Diabetes Study Group.Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)[].The Lancet.1998 被引量：1
-
9中华医学会糖尿病学分会著..中国2型糖尿病防治指南 2010年版[M].北京:北京大学医学出版社,2011:85.
同被引文献31
-
1Garber A J,Abrahamson MJ,Barzilay JI. AACE comprehensive diabetes management algorithm 2013[J].Endocrine Practice,2013.327-336. 被引量：1
-
2Inzucchi SE,Bergenstal RM,Buse JB. Management of hyperglycemia in type 2 diabetes:a patient-centered approach:position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)[J].Diabetes Care,2012.1364-1379. 被引量：1
-
3Whittingham JL,Havelund S,Jonassen I. Crystal structure of a prolonged-acting insulin with albumin-binding properties[J].Biochemistry,1997.2826-2831. 被引量：1
-
4Heise T,Pieber TR. Towards peakless,reproducible and longacting insulins.An assessment of the basal analogues based on isoglycaemic clamp studies[J].Diabetes, Obesity and Metabolism,2007.648-659. 被引量：1
-
5Khunti K,Caputo S,Damci T. The safety and efficacy of adding once-daily insulin detemir to oral hypoglycaemic agents in patients with type 2 diabetes in a clinical practice setting in l0 countries[J].Diabetes, Obesity and Metabolism,2012.1129-1136. 被引量：1
-
6Meneghini LF,Rosenberg KH,Koenen C. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine:clinical practice experience from a German subgroup of the PREDICTIVE study[J].Diabetes, Obesity and Metabolism,2007.418-427. 被引量：1
-
7Blonde L,Merilainen M,Karwe V. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue:an assessment of two different fasting plasma glucose targets-the TITRATE study[J].Diabetes, Obesity and Metabolism,2009.623-631. 被引量：1
-
8Caputo S,Andersen H,Kaiser M. Effect of baseline glycosylated hemoglobin Alc on glycemic control and diabetes management following initiation of once-daily insulin detemir in real-life clinical practice[J].Endocrine Practice,2013.462-470. 被引量：1
-
9Danne T,Lupke K,Walte K. Insulin detemir is characterized by a consistent pharmacokinetic profile across agegroups in children,adolescents,and adults with type 1 diabetes[J].Diabetes Care,2003.3087-3092. 被引量：1
-
10Malek R,Gonzalez-Galvez G,El Naggar N. Safety and effectiveness of insulin detemir in different age-groups in the A1 chieve study[J].Diabetes Therapy,2013.77-90. 被引量：1
-
1徐善超,高跃进,顾艳铃.桂利嗪与尼莫地平对离体血管的舒张作用[J].药学实践杂志,2008,26(5):343-345. 被引量：2
-
2陈欣.用止咳药几点注意[J].养生大世界（B版）,2007(8):45-45.
-
3钱琦.止咳药，选对才有效[J].医食参考,2013(1):25-25.
-
4陆明.6类干咳细辨病因[J].大众医学,2009(1):78-79.
-
5杨丽娜,乔楠,胡敏予,陈继华,林茜,周光宇,魏薇,朱柳凤.鞣花酸对小鼠酒精性肝损伤的保护作用[J].吉林大学学报（医学版）,2015,41(5):956-960. 被引量：5
-
6苏桂兰,王薇.中枢性与末梢性镇咳药[J].中国药店,2002(9):89-89. 被引量：4
-
7何雄生,刘光.前列腺素与消化性溃疡[J].广东药学,1994,4(1):7-9.
-
8蔡德辉,陈守坚,凌燕清,胡艳,范祥春.麻醉诱导期深呼吸法对舒芬太尼诱发咳嗽反应的影响[J].中国实用医药,2016,11(21):200-201. 被引量：2
-
9顾晓燕,殷凯生.氨茶碱对哮喘小鼠气道树突状细胞作用的研究[J].中国呼吸与危重监护杂志,2002,1(3):140-143. 被引量：5
-
10匡长春,何文,罗顺德,宋金春.去甲斑蝥素壳聚糖纳米粒在小鼠体内分布及肝靶向作用[J].中国医院药学杂志,2005,25(6):527-530. 被引量：17
